Collaborations

Immusol initiates collaboration to advance oncology drug-discovery efforts

Published in Cancer Weekly, July 20th, 2004

Immusol has initiated a strategic collaboration with Affymetrix, Inc., (AFFX) that will facilitate the discovery and characterization of new as well as existing targets for cancer therapies.

Specific terms of the deal were not disclosed.

Immusol will utilize Affymetrix GeneChip technology to identify distinct oncology pathways from its engineered tumor cells in biological assays. These modified cancer cells were developed at Immusol by specific down-regulation of tumor suppressors or oncogenes. Using GeneChip brand technology, expression of associated, affected genes will be analyzed and compared.

The program aims to elucidate...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-07-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry